Replies to post #383499 on Innovation Pharmaceuticals Inc (IPIX)

[WiseTrader55]

Everyone needs to read this post. Has so many good points. Happy Veterans Day!

[EnduringPain]

Sanest post of the day. Wish results had been better but glade the wait is over.

[TradingPro]

This is more than Covid, agree. Mild to Moderate is a better trial. I was worried about being to far gone on viral load for B to have any impact. Also will be trialed for other indications. Government funding still out there. At these prices worth it to hold.

[shazamm]

Well said Irish Guy!

[george h]

Great perspective IrishGuy.
With 50 Million shares traded by 10:15 today, just think of all the naked short shares covered. A year from now, those selling now will be kicking themselves in the butt.
I'm buying today!
gh

[sox040713]

I know what you meant, but nothing has changed for Brilacidin in the past two years should ring alarm bells.

1. B-OM - Still no BP is willing to partner despite hiring Locust Walk twice. The BP who signed a term sheet backed out after doing DD.

2. B-ABSSSI - Still no partner despite positive Phase 2b result.

3. B-UP - Alfasigma is in no hurry advancing it.

By shifting shareholder's focus to COVID, Leo wasted another two years of B's patent life. The only thing changed is the total OS has doubled. Leo diluted shareholders from 212M shares in 11/2019 to 437M shares in 11/2021.

I'll repeat for those who's willing to listen. Not able to find a partner for B-ABSSSI and B-OM after all these years is a big red flag.

While I’m disappointed it didn’t help those suffering, I don’t think it changes much. At the end of the day, the original purpose and path for Brilacidin hasn’t really changed.

[thefamilyman]

To add some more of that “perspective?.. I was afraid from the start that the patients in the “moderate to severe” category might be too far into the disease process to take optimal advantage of Brilacidin’s anti-viral capabilities. But I felt that I had to trust that all the brains involved had reason to select the moderate to severe category. Now, given the results of this trial, I am even less optimistic about those compassionate use cases. However, the mild to moderate cases should be in Brilacidin’s sweet spot. The two new drugs are both given orally (pills) but they both apparently have limited effectiveness as well as the potential for serious side effects. If Brilacidin excels in mild to moderate, it will still be the safest drug capable of making a difference for patients suffering from Covid-19 and possibly many other viruses.

Based on this and the many other irons IPIX has in the fire, I added almost 10% to my holdings today.

Irish said and I agree,

I think some perspective is required today. Brilacidin was never about Covid.